NYSE$STE

STERIS PLC · Q2 2025 earnings

Q2 2025 earnings · · Investor relations

Briefing

Announced financial results for fiscal 2025 second quarter, showing revenue increase and reiterated fiscal 2025 outlook.

STERIS reported a 7% increase in total revenue from continuing operations, reaching $1.3 billion. The company reiterated its full year outlook for fiscal 2025, with adjusted EPS increasing to $2.14.

  • Total revenue from continuing operations increased 7%; constant currency organic revenue grew 7%.
  • As reported EPS from continuing operations increased to $1.51; adjusted EPS increased to $2.14.
  • Healthcare revenue grew 9% to $944.2 million, driven by improvements in consumable and service revenue.
  • Fiscal 2025 outlook reiterated, with expected revenue increase of 6.5-7.5% and adjusted EPS in the range of $9.05 to $9.25.

Headline financials

Total Revenue

$1.33B

Previous: $1.34B-1.0%
EPS

$1.51

Previous: $2.03-25.6%
Capital Expenditures

-$210M

Previous: -$150M-40.1%
Free Cash Flow

$344M

Previous: $277M+24.2%
Net Income

$150M

Previous: $115M+30.1%
Operating Income

$220M

Previous: $186M+18.2%
Gross Profit

$579M

Previous: $594M-2.5%
Cash & Equivalents

$172M

Previous: $214M-19.4%
Total Assets

$10.2B

Previous: $11.3B-9.2%
R&D Expense

$27M

No prior period
Stock-Based Comp

$20.8M

Previous: $20.7M+0.5%

Revenue & EPS history

STERIS · Revenue · Quarterly

$1.33B

Q2 2025-1%vs Q2 2024
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

STERIS · $1.59B total across 3 segments · Q4 2027

  • Healthcare
    $1.14B
  • Applied Sterilization Technologies
    $289M
  • Life Sciences
    $163M

Forward guidance

For fiscal 2025, the company expects as reported revenue to increase 6.5-7.5%. Constant currency organic revenue from continuing operations is anticipated to increase 6-7%. Adjusted earnings per diluted share from continuing operations is anticipated to be in the range of $9.05 to $9.25.

Tailwinds

  • As reported revenue to increase 6.5-7.5%.
  • Currency is expected to be slightly favorable to revenue in fiscal 2025.
  • Constant currency organic revenue from continuing operations is anticipated to increase 6-7%.
  • Adjusted earnings per diluted share from continuing operations is anticipated to be in the range of $9.05 to $9.25.
  • Free cash flow is expected to be approximately $700 million.

Headwinds

  • Capital expenditures are anticipated to be approximately $360 million.
  • Effective tax rate of approximately 23% is assumed.
  • Uncertainties related to tax treatments under the TCJA and the IRA.
  • Potential for increased pressure on pricing or costs that leads to erosion of profit margins, including as a result of inflation.
  • Possibility of reduced demand, or reductions in the rate of growth in demand, for STERIS’s products and services.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2025

Historical avgQ2 2025

+0.5%

Avg return

Earnings day

+1.0%

Avg return

5 days after

+1.3%

Avg return

30 days after

59%

38 / 64 earnings

Positive

+12.9%

Q4 2014

Best reaction

-11.4%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2027+0.0%+7.2%+2.8%
Q3 2026-7.7%-7.4%-12.8%
Q2 2026+7.0%+9.7%+8.3%
Q4 2025+8.6%+10.1%+6.1%
Q3 2025+2.1%+1.1%+5.4%
Q2 2025-5.2%-2.5%-5.1%
Q1 2025-1.8%-0.8%+0.5%
Q4 2024+6.2%+9.2%+6.6%
Q3 2024-2.5%-0.4%+3.4%
Q2 2024-5.1%-8.4%-7.1%
Q1 2024+1.0%+0.2%+1.8%
Q4 2023+11.2%+12.7%+10.6%
Q3 2023-11.4%-9.5%-18.2%
Q2 2023+3.5%+2.6%+17.3%
Q1 2023-8.8%-4.7%-10.0%
Q4 2022+1.4%+1.2%+2.6%
Q3 2022+4.6%+1.3%-2.1%
Q2 2022-5.5%-4.8%-6.4%
Q1 2022+0.6%+1.2%+0.2%
Q4 2021-3.6%-3.1%+1.9%
Q3 2021-1.9%-1.7%-8.1%
Q2 2021-0.5%+2.5%+8.8%
Q1 2021-1.0%-3.4%+2.5%
Q4 2020+1.2%+7.0%+1.8%
Q3 2020+6.1%+10.2%-5.0%
Q2 2020+2.3%+2.6%+8.4%
Q1 2020+3.0%+4.1%+3.0%
Q4 2019+1.1%+3.2%+10.2%
Q3 2019+1.9%+3.1%+3.6%
Q2 2019+7.0%+7.4%+5.4%
Q1 2019-0.7%-1.1%-1.9%
Q4 2018+4.7%+4.6%+8.6%
Q3 2018-4.7%-2.8%+7.8%
Q2 2018-6.0%-6.6%-3.9%
Q1 2018+4.9%+3.3%+5.8%
Q4 2017+1.4%-0.4%+6.4%
Q3 2017-6.5%-5.7%-3.4%
Q2 2017-3.0%+0.5%-2.0%
Q1 2017-1.6%-1.9%-2.0%
Q4 2016-0.5%
Q3 2016-1.9%
Q2 2016+6.4%
Q1 2016+0.7%
Q4 2015+2.5%
Q3 2015+1.1%
Q2 2015+3.5%
Q1 2015+0.3%
Q4 2014+12.9%
Q3 2014+0.5%
Q2 2014-3.6%
Q1 2014-3.6%
Q4 2013+8.3%
Q3 2013+1.4%
Q1 2013+1.4%
Q2 2013+1.1%
Q4 2012-0.3%
Q3 2012+0.8%
Q1 2012+0.8%
Q2 2012-4.4%
Q4 2011+0.3%
Q3 2010+0.2%
Q1 2010+0.2%
Q2 2010+0.8%
Q4 2010-0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro